Clik here to view.
Arteaus’ Final Chapter: Monetization Of The Emgality Royalties
Back in September 2018, the FDA approved Lilly’s Emgality, an anti-CGRP antibody therapy, for the preventative treatment of episodic and chronic migraine. Arteaus Therapeutics, a biotech company...
View ArticleClik here to view.
Sharing An Innate Desire To Address Inflammation: Novartis and IFM Team Up
Today Novartis announced the acquisition of IFM Therapeutics’ portfolio of NLRP3 antagonists, via the purchase of IFM Tre, a subsidiary of IFM (here, here). These immunomodulatory medicines target the...
View ArticleClik here to view.
Cats And The Future Of Machine Learning In Drug Discovery
This blog was written by Jonathan Montagu, CEO and founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC. The predictions around the impact of artificial intelligence...
View ArticleClik here to view.
Sheer Heart Attack: What Happens When Your Partner Gets Acquired in The...
This blog was written by Tariq Kassum, COO of Obsidian Therapeutics, as part of the From The Trenches feature of LifeSciVC. Every morning before I go to work, I review my calendar for the day. This...
View ArticleClik here to view.
Why Reputation Is More Important Than Ever For Biotech Companies … And What...
This blog was co-written by Deanna Petersen, Chief Business Officer of AVROBIO, and Paul Newman, head of Corporate Communications, as part of the From The Trenches feature of LifeSciVC. “It takes...
View ArticleClik here to view.
Maybe It’s Innate
This blog was written by Samantha Truex, Atlas EIR and CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC. Recently I read the article What’s Wrong With Me? that I saw re-posted...
View ArticleClik here to view.
An Encyclopedia Of Advice For Startup Boards
Startups management teams often have a love-hate relationship with their Board of Directors: while Boards can be hugely helpful and constructive in the best of times, they can be dysfunctional and...
View ArticleClik here to view.
A Decade of Discovery
This blog was written by Jeb Keiper, CEO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. It is with great excitement that we at Nimbus are ringing in our 10th...
View ArticleClik here to view.
Getting Clinical On New Drug Launches
The IQVIA Institute released a data-rich report in April 2019 on the state of clinical R&D in the US pharmaceutical industry titled “The Changing Landscape of Research and Development: Innovation,...
View ArticleClik here to view.
Targeted Protein Degradation Comes of Age
This blog was written by Nello Mainolfi, CSO and co-founder of Kymera Therapeutics, as part of the From The Trenches feature of LifeSciVC. Translation of well validated biology into therapeutics...
View ArticleClik here to view.
Biotech Startups And The Hard Truth Of Innovation
Gary Pisano’s recent Harvard Business Review piece, The Hard Truth About Innovative Cultures, beautifully frames up how innovative corporate environments are frequently misunderstood. Innovative...
View ArticleSPR994: A Long Shot, With Lots Of Twists And Turns To Phase III
This blog was written by Ankit Mahadevia, CEO and founder of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. At Spero we are privileged to be enrolling our pivotal study for...
View ArticleClik here to view.
Of Microbes And Men
This blog was written by Aoife Brennan, CEO of Synlogic Therapeutics, as part of the From The Trenches feature of LifeSciVC. I am the CEO of Synlogic, a synthetic biology company, where the focus of...
View ArticleTips for Industry-Academia Collaboration
This blog was written by Samantha Truex, Atlas EIR and CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC. Some of the most promising and innovative research underlying biotech...
View ArticleClik here to view.
Goldilocks And GMP
This blog was written by Aoife Brennan, CEO of Synlogic Therapeutics, as part of the From The Trenches feature of LifeSciVC. New therapeutic platforms, like those based on cell and gene therapy,...
View ArticleThe Creation Of Biotech Startups: Evolution Not Revolution
The startup paradigm for the creation and funding of new biotech companies has evolved enormously over the past two decades. Recently there’s been a pair of articles from Tech VCs about applying...
View ArticleNavigating The Unknown: Practical Thoughts On A Team That Can Rise To The...
This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. One of the joys of building a company is that meeting one’s milestones...
View ArticleClik here to view.
Early Company Evolution – People, Pipeline, and Purse
This blog was written by Mark Manfredi, CEO of Kyn Therapeutics, as part of the From The Trenches feature of LifeSciVC. “Time flies when you’re having fun.” That’s how I feel as I reflect on the first...
View ArticleClik here to view.
Leave No Stone Unturned: A Pipeline Story
This blog was written by Deanna Petersen, CBO of AVROBIO (@dmp9818), as part of the From The Trenches feature of LifeSciVC. Building a leading gene therapy pipeline in under two years (and a lot of air...
View ArticleClik here to view.
Ode to Patients
This blog was written by Samantha Truex, CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC. Due to meetings in London on a Friday and in Dortmund on the following Monday, I spent...
View Article
